{"id":63966,"date":"2026-11-09T09:59:45","date_gmt":"2026-11-09T09:59:45","guid":{"rendered":"https:\/\/ibima.eu\/?p=63966"},"modified":"2026-11-09T09:59:56","modified_gmt":"2026-11-09T09:59:56","slug":"proof-eu","status":"publish","type":"post","link":"https:\/\/ibima.eu\/es\/proof-eu\/","title":{"rendered":"PROOF"},"content":{"rendered":"

[et_pb_section fb_built=\u00bb1″ _builder_version=\u00bb4.27.6″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb25px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][et_pb_row _builder_version=\u00bb4.25.1″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][et_pb_column type=\u00bb4_4″ _builder_version=\u00bb4.25.1″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][et_pb_heading title=\u00bbrePurposing tReatment fOr Osteogenesis imperFecta\u00bb _builder_version=\u00bb4.27.7″ _module_preset=\u00bbdefault\u00bb title_font=\u00bb||||||||\u00bb title_text_align=\u00bbcenter\u00bb title_text_color=\u00bb#0C71C3″ module_alignment=\u00bbcenter\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][\/et_pb_heading][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=\u00bb2_3,1_3″ _builder_version=\u00bb4.25.1″ _module_preset=\u00bbdefault\u00bb custom_padding=\u00bb30px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][et_pb_column type=\u00bb2_3″ _builder_version=\u00bb4.25.0″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][et_pb_text _builder_version=\u00bb4.27.7″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb]<\/p>\n

\n
\n
\n
\n
\n
\n

Financed by<\/span><\/strong> : Instituto de Salud Carlos III (ISCIII)<\/span><\/span><\/p>\n

Program<\/strong>: ERDERA \u2013 Joint Transnational Call 2025 \u201cPreclinical therapy studies for rare diseases using small molecules and biologicals \u2013 development and validation\u201d<\/span><\/p>\n

Project National Reference:<\/strong> AC25\/00043<\/span><\/p>\n

Role in the project:<\/strong> Partner<\/span><\/p>\n

Duration:<\/b> April 2026 to March 2029<\/span><\/p>\n

\u00a0<\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n

\n
\n
\n
\n
\n
\n

Contact: Lidiia Zhytnik<\/span><\/p>\n

Implementation Centre: IBIMA Platform BIONAND\u00a0<\/a><\/span><\/p>\n

Research group of IBIMA involved: Skeletal Biomedicine Research Group<\/a><\/span><\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=\u00bb1_3″ _builder_version=\u00bb4.25.0″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][et_pb_image src=\u00bbhttps:\/\/ibima.eu\/wp-content\/uploads\/2026\/10\/LOGO-PROOF.png\u00bb title_text=\u00bbLOGO PROOF\u00bb align=\u00bbright\u00bb _builder_version=\u00bb4.27.7″ _module_preset=\u00bbdefault\u00bb transform_scale=\u00bb162%|162%\u00bb transform_translate=\u00bb-14px|54px\u00bb width=\u00bb69%\u00bb max_width=\u00bb71%\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][\/et_pb_image][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00bb4.25.1″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||-48px||false|false\u00bb custom_padding=\u00bb50px||50px||true|false\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][et_pb_column type=\u00bb4_4″ _builder_version=\u00bb4.25.0″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][et_pb_heading title=\u00bbAbstract\u00bb _builder_version=\u00bb4.27.7″ _module_preset=\u00bbdefault\u00bb title_font=\u00bb||||||||\u00bb title_text_color=\u00bb#0C71C3″ global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][\/et_pb_heading][et_pb_text _builder_version=\u00bb4.27.7″ _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb0px||19px||false|false\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb]<\/p>\n

Osteogenesis imperfecta (OI) is a rare disease that makes bones very fragile and prone to fractures. There is currently no approved medicine for it worldwide, apart from bisphosphonates, which are available in Italy and Japan and help slow bone loss. PROOF explores whether RAVICTI, a drug already used to treat the rare urea cycle disorder (UCD), could also help people with OI. Its active ingredient, 4-phenylbutyrate (4-PBA), may relieve the cellular stress caused by the accumulation of faulty collagen and improve collagen production.<\/p>\n

To test this, the consortium combines animal models of the disease with human cells grown in the laboratory. The team brings together scientists and doctors specialised in OI, so that promising results can quickly move to testing in patients. The company that makes RAVICTI supplies the medicine for the study, and the project works with Remedi4All, a European organisation specialised in drug repurposing, and with MetabERN, the network of UCD patients already treated with the drug.<\/p>\n

People with OI are involved from the very beginning through the patient groups in the consortium, so that the research focuses on real patient needs.<\/p>\n

[\/et_pb_text][et_pb_heading title=\u00bbPartners\u00bb admin_label=\u00bbT\u00edtulo\u00bb _builder_version=\u00bb4.25.1″ _module_preset=\u00bbdefault\u00bb title_font=\u00bb||||||||\u00bb title_text_color=\u00bb#0C71C3″ custom_margin=\u00bb30px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb][\/et_pb_heading][et_pb_text _builder_version=\u00bb4.27.7″ _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbpost_content\u00bb]<\/p>\n

<\/a><\/p>\n